Articles: treatment.
-
Clinical breast cancer · Apr 2020
Multicenter Study Observational StudyDuctal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients.
Ductal carcinoma in situ (DCIS) represents 15% of all breast cancers in France. The first national survey was conducted in 2003. The present multi-center real-life practice survey aimed at assessing possible changes in demographic, clinical, pathologic, and treatment features. ⋯ The clinical practice identified in this survey complies with French DCIS guidelines. About 10% of patients with low-grade DCIS may be eligible to participate in treatment de-escalation trials.
-
Randomized Controlled Trial Multicenter Study
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
Among some patients with human immunodeficiency virus type 1 (HIV-1) infection who have undergone multiple antiretroviral therapies and have limited options for treatment, new classes of antiretroviral drugs with novel mechanisms of action are needed. Fostemsavir is the prodrug of temsavir, a first-in-class investigational HIV-1 attachment inhibitor. ⋯ In patients with multidrug-resistant HIV-1 infection with limited therapy options, those who received fostemsavir had a significantly greater decrease in the HIV-1 RNA level than those who received placebo during the first 8 days. Efficacy was sustained through 48 weeks. (Funded by Bristol-Myers Squibb and GSK/ViiV Healthcare; BRIGHTE ClinicalTrials.gov number, NCT02362503.).
-
Randomized Controlled Trial Multicenter Study Comparative Study
Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial.
Patients diagnosed with advanced HIV infection have a poor prognosis despite initiation of combined antiretroviral therapy (c-ART). ⋯ INSERM-ANRS (French National Agency for Research on AIDS).
-
Randomized Controlled Trial Multicenter Study
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
More effective and safer treatments are needed for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. ⋯ Among patients with severe ANCA-associated vasculitis, the use of plasma exchange did not reduce the incidence of death or ESKD. A reduced-dose regimen of glucocorticoids was noninferior to a standard-dose regimen with respect to death or ESKD. (Funded by the U.K. National Institute for Health Research and others; PEXIVAS Current Controlled Trials number, ISRCTN07757494; ClinicalTrials.gov number, NCT00987389.).